GSK's strategy can be seen as a response to the challenges of drug development, particularly the high failure rates at the discovery stage. By entering once the biology is clearer and the commercial angle is easier to define, GSK aims to improve its odds of translating pipeline assets into approved products. However, this approach also has limitations, as new entrants may struggle to compete in spaces where first movers have already defined expectations. Furthermore, the broad early-stage pipeli...